patent.fyi
Applications  /  US 2026/0356834
United States Patent Application Publication

US 2026/0356834 A1

Published
Nov 12, 2026
Filed
May 10, 2024
Earliest date on the face
May 12, 2023
Classification
C07D 471/04
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Cyano group at R1

What ifWhat if R1 were a cyano group?
Claim language“C1-3haloalkyl, or halo”

The cyano group attaches through its carbon atom and projects along a linear carbon–nitrogen axis. It withdraws electron density through the attachment bond and presents a terminal nitrogen that accepts hydrogen bonds.

1.2Carboxamide group at R2

What ifWhat if R2 were a primary carboxamide?
Claim language“C1-3alkoxy, or halo”

The carboxamide attaches through its carbonyl carbon. Its carbonyl oxygen accepts hydrogen bonds, and its NH₂ group donates them.

1.3Oxetanyl ring at R3

What ifWhat if R3 were an oxetan-3-yl group?
Claim language“C3-6cycloalkyl, or halo”

The four-membered ring attaches through the carbon opposite its oxygen atom. The ring fixes the position of the ether oxygen relative to the attachment point and presents it as a hydrogen-bond acceptor.

1.4Ethynyl group at R4

What ifWhat if R4 were an ethynyl group?
Claim language“C3-6cycloalkyl, or halo”

The substituent attaches through one carbon of a carbon–carbon triple bond. The linear bond geometry projects the terminal carbon along the attachment axis with a narrow cross-section.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Water sample recovery control

A formula (I) compound serves as a recovery control in a water testing workflow. A measured amount of the compound is added to one aliquot before solid phase extraction and to a matched aliquot after extraction. Liquid chromatography with mass spectrometry measures the compound in both extracts, and the ratio of the background-corrected peak areas estimates extraction recovery.

Component substitution

Methoxy substitution at the R2 position

A methoxy group occupies R2 in place of hydrogen on the formula (I) scaffold. R1 and R3 through R5 have the same assignments in both members of the matched pair. Proton nuclear magnetic resonance identifies the methoxy signal, and a long-range proton–carbon correlation links that signal to the carbon at R2.

Parameter or scale variation

Two loading levels for solubility measurement

Separate vials contain the same formula (I) compound at nominal loadings of 0.5 and 5 mg/mL in pH 7.4 buffer. Both suspensions are agitated at 25 °C and sampled at 24 and 48 hours. Centrifugation removes suspended solids, and liquid chromatography measures the dissolved concentration in each supernatant. Agreement across time points and loadings, with residual solid present, supports an equilibrium solubility measurement.

Combination with existing systems

Perfused neuronal recording with electrode arrays

A perfusion manifold delivers a formula (I) compound in culture medium to neuronal cultures grown on a microelectrode array. The manifold switches between vehicle, compound solution, and wash medium while the array continuously records extracellular activity. The recording software compares burst frequency and duration during each exposure with the vehicle baseline.

Dissolution testing with inline sample collection

A capsule containing a formula (I) compound or its salt is placed in a stirred dissolution vessel held at 37 °C. A sampling pump draws aliquots through a filter at 5, 15, 30, and 60 minutes into collection vials. Liquid chromatography measures the dissolved compound, and the cumulative release calculation accounts for drug removed in earlier samples.

Automated or data-driven variant

Software enumeration of position-specific substituent sets

A molecular graph editor stores the formula (I) scaffold with five labeled attachment points and a fragment list for each point. A script attaches one allowed fragment at each site, checks atom valences, and generates a canonical representation that preserves specified stereochemistry. The script removes duplicate structures and exports the unique structures with their R1 through R5 assignments.

Specific version of a part

Hydroxyethyl chain at R5

A two-carbon chain connects the attachment point to a terminal hydroxyl group. Rotation about the carbon–carbon bond changes the hydroxyl orientation, and the hydroxyl forms hydrogen bonds with water.

Trifluoromethyl group at R1

A trifluoromethyl group attaches through its carbon atom. The three carbon–fluorine bonds produce a strong electron-withdrawing inductive effect at the attachment site.

Methoxy group at R2

An oxygen atom connects the scaffold to a methyl group. The ether oxygen serves as a hydrogen-bond acceptor.

Cyclopropyl ring at R3

A saturated three-carbon ring attaches through one of its ring carbons. The ring constrains the positions of the other two carbons relative to the attachment carbon.

Branched six-carbon chain at R5

A 2-methylpentyl group attaches through carbon 1 of the five-carbon chain. A methyl branch at carbon 2 places additional steric bulk one bond beyond the attachment carbon.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 11,214,574 B2
Published
Jan 4, 2022
Filed
Jun 1, 2020
Class
C07D 487/04
Document BUS 2022/0235006 A1
Published
Jul 28, 2022
Filed
Jan 21, 2022
Class
C07D 213/81
Claim 1
Document A
Document B
1.1A compound of formula (I), or a salt thereof: wherein, R1 is hydrogen, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, or halo
or a pharmaceutically acceptable salt or solvate thereof, wherein A is N or C—R3; R1 is H, halo, —C1-C6alkyl, —C1-C6alkoxy, —C1-C4haloalkyl, —C3-C6cycloalkyl, —C3-C6halocycloalkyl, —C1-C6alk-O—C1-C6alkyl, —C1-C6alk-S(O)—C1-C6alkyl, —C1-C6alk-S(O)2—C1-C6alkyl, —CR6R6′CN, —NR6R6′, —NHCR6R6′CN, —NHCONR6R6′, —NHC(O)OR7, NHC(O)—C1-C6alkyl, NHC(O)—C1-C6haloalkyl, —NH—C1-C6alk-C(O)—C1-C6alkyl, —NHC(S)NR6R6′, —NH—O—R6, or —NH—NR6R6′;
A · US 11,214,574 B2 · ¶ 11
A compound of general formula (I) including all tautomeric forms, all enantiomers, isotopic variants, and salts and solvates thereof: wherein: R1 is selected from methyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, ethynyl and CN; or when R2 and R3 together with the carbon atom to which they are attached form a 4- to 6-membered carbocyclic ring substituted, in addition to the R1 group, with OH, halo, methyl or CH2OH, R1 may also
B · US 2022/0235006 A1 · claim 1
1.2R2 is hydrogen, C1-3alkyl, C1-3alkoxy, or halo
R2 is H, halo, —C1-C6alkyl, or NH2;
A · US 11,214,574 B2 · ¶ 11
1.3R3 is hydrogen, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, C3-6cycloalkyl, or halo
R3 is H, halo, —C1-C6alkyl, —C1-C6alkoxy, —C2-C6alkenyl, or —C2-C6alkynyl;
A · US 11,214,574 B2 · ¶ 11
R3 is selected from H and methyl; or R2 and R3 together with the carbon atom to which they are attached form a 3- to 10-membered carbocyclic or oxygen-containing heterocyclic ring system, either of which is optionally substituted, in addition to the R1 group, with one or more substituents selected from OH, halo, C1-4 alkyl, C1-4 alkyl substituted with one or more OH substituents, and C1-4 haloalkyl; or R1, R2 and R3 together with the carbon atom to which they are attached com
B · US 2022/0235006 A1 · claim 1
1.4R4 is hydrogen, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, C3-6cycloalkyl, or halo
R4 is H, —C1-C6alkyl, —C1-C6haloalkyl, —C2-C6alkenyl, or —C2-C6alkynyl;
A · US 11,214,574 B2 · ¶ 11
R4 is H or halo; each of R5 and R7 is independently selected from H, halo, C1-3 alkyl and C1-3 haloalkyl;
B · US 2022/0235006 A1 · claim 1
1.5R5 is hydrogen, C1-10alkyl, C1-10haloalkyl, C3-6cycloalkyl, or halo.

An empty cell means only that no passage was reproduced there.

Statements in these documents
The disclosure is directed to PRMT5 inhibitors and methods of their use.
A · US 11,214,574 B2 · ¶ 2
Integrating data from comprehensive genomic profiling of cancer cell lines and from functional characterization of cancer cell dependencies, it has been recently discovered that loss of the enzyme methylthioadenosine phosphorylase (MTAP) confers a selective dependence on protein arginine methyltransferase 5 (PRMT5) and its binding partner WDR77.
A · US 11,214,574 B2 · ¶ 7
In cystic fibrosis, where loss of function mutations in CFTR attenuates the ability of the airway to secrete fluid, the % solids can be increased to 15% which is believed to contribute towards the plugging of small airways and failure of mucus clearance.
B · US 2022/0235006 A1 · ¶ 4
Strategies to increase the hydration of the airway mucus include either the stimulation of anions and thereby fluid secretion or the inhibition of Na+ absorption.
B · US 2022/0235006 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0356834 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356834/, SHA-256 c0bd58ee6febc2021d589fd7bd9045ba9cc1414ba5c4db11000a65814830a9bf
First published
Permanent addresshttps://patent.fyi/US20260356834/
Content fingerprint (SHA-256)c0bd58ee6febc2021d589fd7bd9045ba9cc1414ba5c4db11000a65814830a9bf
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi